Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof

A conjugate compound consisting of the formula:

• H-(L)i-(X)m
• wherein:
• i) H is albumin;
• ii) L is a chelating agent selected from the group consisting of 22,2′,2″,2″-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), 2,2′,2″-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (NOTA), trientine hydrochloride (TETA), 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine) (AAZTA), Nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (DO3A), NOC, DOTAGA, and/or combinations thereof;
• and
• iii) X is a radioisotope selected from the group consisting of copper-64, copper-67, fluorine-18, gallium-68, gallium-67, gallium-66, lutetium-177, yttrium-86, yttrium-90, zirconium-89, bismuth-213, bismuth-212, actinium-225, astatine-211, gold-198, gold-199, lead-212, rhenium-188, rhenium-186, and/or combinations thereof;
• and
• wherein i is an integer of value 1-5 and m is an integer of 1-5;
• and
• wherein the said conjugate compound has a mean particle size distribution (d50) of from about 25 nm to about 90 nm and the minimum particle size distribution (d10) of the conjugate compound ranges from about 15 nm to about 40 nm and the maximum particle size distribution (d90) of the conjugate compound ranges from about 40 nm to about 150 nm;
• and
• wherein the conjugate compound has a polydispersity index less than 0.5;
• and
• wherein the conjugate compound further consists of one or more target specific ligands conjugated to the albumin;
• and
• wherein the conjugate compound has an initial radiochemical purity of at least 95% immediately after preparation.